THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES

Abstract

The present disclosure provides for treating neurodegenerative diseases comprising administering leucine, acetyl-leucine or a pharmaceutically acceptable salt thereof.

(Fig. 14)